Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PA100
- Development stage
- Discontinued
- Lead developer
- Panacea Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PA100 (also known as PAN-622) is a humanized monoclonal antibody developed by Panacea Pharmaceuticals that targets Human Aspartyl (Asparaginyl) beta-Hydroxylase (HAAH). HAAH is an enzyme that is highly overexpressed on the surface of various malignant tumor cells, including those of the liver, lung, colon, and pancreas, while remaining virtually undetectable in normal tissues. By binding to HAAH, PA100 is designed to inhibit the enzyme's activity, which is involved in cell motility and invasiveness, thereby potentially suppressing tumor growth and metastasis. The drug was primarily investigated for the treatment of hepatocellular carcinoma (liver cancer) and other solid tumors in early-phase clinical trials.
- Other names
- anti-HAAH monoclonal antibody
02
Targets
ASPH (Aspartyl/asparaginyl beta-hydroxylase)
Beyond the preview
Go deeper on PA100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PA100.